This webinar presents the patient perspective, electrophysiological research, and technologies used as we work towards a potential treatment for KCNC1-related disorders.

Clear decision-making data for your project team is vital to ensure you avoid costly issues related to QTc and QRS cardiac liabilities in the clinic.

Hear from industry experts, Derek Leishman (VP Translational and Quantitative Toxicology, Eli Lilly and Company) and Steve Jenkinson (Metrion).